The co-expression of DNMT1 and the Enhancer of zeste homolog 2 (EZH2), alongside their correlation with poor prognostic markers in prostate cancer, underscores the importance of DNMT1 in maintaining tumor-promoting epigenetic landscapes (Li et al., 2022). This evidence concerns the gene EZH2 and prostate cancer.